Noble Drugs Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
- Paid Up Capital ₹ 9.91 M
- Company Age 41 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Satisfied Charges ₹ 1.73 Cr
- Revenue Growth 47802.33%
- Profit Growth -1657.10%
- Ebitda -1597.30%
- Net Worth
- Total Assets 2.40%
About Noble Drugs
Noble Drugs Limited (NDL) is a Public Limited Indian Non-Government Company incorporated in India on 21 March 1983 and has a history of 41 years and 11 months. Its registered office is in Nashik, Maharashtra, India.
The Corporate was formerly known as Noble Drugs P Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 9.91 M.
The company has closed loans amounting to ₹1.73 Cr, and has no open charges as per Ministry of Corporate Affairs (MCA) records.
Dnyaneshwar Dhamne, Shriram Dhamne, and Vilas Dhamne serve as directors at the Company.
Company Details
- Location
Nashik, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24100MH1983PLC029592
- Company No.
029592
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
21 Mar 1983
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Noble Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Dnyaneshwar Dhamne  | Managing Director | 20-Nov-1983 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Vilas Dhamne | Director | 01-Mar-1996 | Current |
| Shriram Dhamne | Director | 29-Jun-1995 | Current |
Financial Performance of Noble Drugs.
Noble Drugs Limited, for the financial year ended 2018, experienced significant growth in revenue, with a 47802.33% increase. The company also saw a substantial fall in profitability, with a 1657.1% decrease in profit. The company's net worth witnessed no change by increase of 0%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth | |||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Noble Drugs?
In 2018, Noble Drugs had a promoter holding of 66.70% and a public holding of 33.30%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Professional Realtors Association Of Nashik PranDnyaneshwar Dhamne is a mutual person
- Etash Life Sciences Limited Liability Pa Rtnership
Vilas Dhamne is a mutual person
- Spiti Construction Private Limited
Vilas Dhamne is a mutual person
Charges (Loans)
₹0
₹1.73 Cr
Charges Breakdown by Lending Institutions
- Bank Of India : 1.16 Cr
- Bamk Of Indai : 0.51 Cr
- Rchants Co-Op Bnak : 0.04 Cr
- Maha Rashtra State Financeal Corporation : 0.02 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 06 Mar 2004 | Bank Of India | ₹0.67 M | Satisfied |
| 23 Jul 2002 | Bank Of India | ₹1.70 M | Satisfied |
| 18 Jun 2002 | Bank Of India | ₹2.37 M | Satisfied |
| 18 Jun 2002 | Bank Of India | ₹0.50 M | Satisfied |
| 18 Jun 2002 | Bamk Of Indai | ₹0.50 M | Satisfied |
How Many Employees Work at Noble Drugs?
Unlock and access historical data on people associated with Noble Drugs, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Noble Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Noble Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.